Intravenous administration of propafenone  by Capucci, Alessandro & Boriani, Giuseppe
1314;
LETTERS TO THE EDITOR
Worldwide Call for Patients With the Bjork .
Shiley Convexo-Concave Heart Valve
I"he purpose of Ibis lever is to into rm you about an effort to notify
people worldwide with the Bjork-Shilcy Convexo-Concave heart
valve of a class action lawsuit in Cincinnati, Ohio . The name of the
lawsuit is Bott lige . elm. I . S6ilrv Inrruyarnted and i".1rerJJ,'. Case
No. C-1-91-25(,, which is pending before Judge S . Arthur Spiegel of
the United State, District Court for the Southern District of Ohio.
,".ccip; .o;,nf ;Lc--;- ul ice„yousvs .achcalga,kediudccidc
whether they want babe part of the class action .
Pfizer Inc and Shiley incorporated recently announced thin they
had entered into a class action acttlemeat agreement involving
recipients of the Bjork-Shilcy 60 and 7(1 degree Convexo-Concave
heart valve . as wc11 as the spou -of those recipients- This agreement
gun, antees benefits to recipients with functioning valves, including
payments from a fund of $80 million or more, depending on the number
ofelaimants .that canheused fortinypurpos including consulunion
with a cardiologist or other health care provider . the settlement also
provides for additional vuPne research and ether benefits . Should the
valve ever haaire, recipients would be promptly compensated
according to a court-approved settlement futmula
.
Valve recipients will he hound by the terms of the settlement, if
approve,] . uuicss they specifically exclude
t hemselves
. i n writing .
from the lawsuii.'1'hmeffe . it is important that informalion about
the settlement he provided to these people and their spouses .
The Court has begun a process to notify recipients and their
spouses worldwide about this agree ent and how they can respond .
By May 22, 1992, all Bjork-Shilcy Convexo-Concave valve recipients
are requested to write :
Stanley M
. Cheslcy . Esq
.
Waite. Schneider . Baylew & Chesley Co . . L.P .A .
1513 Central Trust lower
Cincinnati . Ohio 45202
FAX : 15171621-0162
DANIELJ . LYONS
. JR .
IApun' (lrrk
Unia
•J 51nno
Moon Cuurr
SuuthmnUi, 1A I if ON,
B'eamra I irisena
Intravenous Administration of Propafenone
As European cardiologists whose practice is devoted largely to
arrhvthmias and amino rhythmic drug smdirsi we must comment on
the article of Boahene et al . (I I on the effects of propafenone and
procainamide on ;trial fibrillation in the Wolf'-Parkinson-White
syndrome . This well designed and very nicely presented paper
compares the electrophysiulogic effects of the two intravenously
infused drugs on RR intervals and their capacity to terminate xtriel
fibrillation . One of the conclusions is that in these patients procain-
amide terminated atriol fibrillation more frequently than did pro-
p
:Bennne Even Jordaens and Clemcat (2) found procainamide more
effective than pnrp'allcrene in preventing inducibility of sustained
ventricular mchycandla. The problem is that in these studies pro-
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cainamide wrs infused at a me, of 12 to IS mglkg body weight, which
is certainly a therapeutic dose
. whereas propafenone was give e
dose of up to I to 2 mglkg over 1(1 min . It has already hear
demonstrated (3) that propafenone requires a relatively longtime to
bind to the myocardium. Thus . considering also the very rapid
decrease in plasma concentration and the rather large distribution
volume (4), to obtain the best effects the intravenous bolus dose
must be followed by :I maintenance infusion of at least (1007 I„
(1.1114 mgrkg per min 15) .
-,c,l
studies
underline the importance of propafenone
infusion~after an intravenous bolus. In the study of Shen et al
. (6)
noninducibility of sustained ventricular tachycandin was obtained
much more frequently by a 2 iug/min propafenone {nfusioa, aftc a
7_
mg/kg propafenone bolus dose, than by a I mglmin infusion . In the
study of Doherty et .d . (71 the dose of propafenone was increased
from I to 2 mg/kg and a constant infusion was added because
induction of ventricular tachycerdia was not prevented in any of the
first 10 patients submitted to electrophysiologic evaluation . In that
study the overall efficacy of intravenous propafenone was very low ;
however . a comparison of different doses is not reported .
Our view, as demonstrated previously (5,81, is that intravenously
administered propafenone has to be infused with a maintenance
dose and this concept has become almost a rule in our country . The
main consequence of these brief considerations is that protocols
involving intravenously administered propafenone and including
only an acute bolus dose should not he considered because they
underestimate the therapeutic efficacy ofthe drug . It is obvious that
more attention given to European scientific publications would
contribute to avoiding confusion and mistakes with respect to
anliarrhyihmic drugs .
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